Posted by Michael Wonder on 12 Feb 2026
Datroway supplemental new drug application submitted in Japan for patients with metastatic triple negative breast cancer Who Are Not Candidates for Immunotherapy
12 February 2026 - Based on results from TROPION-Breast02 showing Datroway significantly improved overall survival versus chemotherapy in this patient population.
Daiichi Sankyo has submitted a supplemental new drug application to Japan’s MHLW for Datroway (datopotamab deruxtecan) for the treatment of adult patients with hormone receptor negative and HER2 negative unresectable or recurrent breast cancer, a subtype commonly referred to as triple negative breast cancer.
